Rani Therapeutics Holdings (RANI) Research & Development (2020 - 2026)

Rani Therapeutics Holdings' Research & Development history runs 7 years deep, the most recent figure standing at $5.2 million for Q1 2026.

• On a quarterly basis, Research & Development fell 21.45% year-over-year to $5.2 million in Q1 2026; TTM through Mar 2026 was $18.8 million, a 26.77% decrease from a year earlier, with the FY2025 full-year figure at $20.2 million, down 24.27% from the prior year.
• Research & Development improved to $5.2 million in Q1 2026 per RANI's latest filing, from $4.9 million in the prior quarter.
• Across five years, Research & Development topped out at $11.2 million in Q3 2023 and bottomed at $3.2 million in Q3 2025.
• The 5-year median for Research & Development is $7.6 million (2024), against an average of $7.5 million.
• Across the five-year window, Research & Development jumped 153.47% in 2022 and plunged 47.81% in 2025, its largest moves.
• Year by year, Research & Development stood at $10.4 million in 2022, then slipped by 26.77% to $7.6 million in 2023, then declined by 10.47% to $6.8 million in 2024, then decreased by 27.91% to $4.9 million in 2025, then gained by 5.13% to $5.2 million in 2026.
• Per Business Quant, the three latest RANI Research & Development figures stand at $5.2 million (Q1 2026), $4.9 million (Q4 2025), and $3.2 million (Q3 2025).